<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085058</url>
  </required_header>
  <id_info>
    <org_study_id>WISP_CU01</org_study_id>
    <nct_id>NCT01085058</nct_id>
  </id_info>
  <brief_title>Predictive Value of the &quot;Cytocapacity Test&quot; Patients With Lymphoproliferative Diseases and High-dose Therapy</brief_title>
  <acronym>CU01</acronym>
  <official_title>Predictive Value of the &quot;Cytocapacity Test&quot; Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigator initiated trial was a prospective, open, single-arm, diagnostic-prognostic&#xD;
      study. Patients who received high-dose therapy with autologous stem cell transplantation for&#xD;
      the treatment of their lymphoproliferative disease were included into the study.&#xD;
&#xD;
      After completion of the high-dose therapy (day -2 with respect to the stem cell&#xD;
      transplantation) the first blood sample A for the cytocapacity test with determination of&#xD;
      leukocytes and neutrophils was taken in the evening of day -1. Directly thereafter the study&#xD;
      medication was administered. The second blood sample B for the cytocapacity test with&#xD;
      determination of leukocytes and neutrophils was taken in the morning of day 0, 12-14 hours&#xD;
      after administration of the study medication. Thereafter the stem cell re-infusion was&#xD;
      performed.&#xD;
&#xD;
      The primary objective of this study was to show that the cytocapacity test with lenograstim&#xD;
      is a useful predictive tool with respect to the risk of post-transplant complications and&#xD;
      prolonged myelosuppression, typically occurring after high-dose chemotherapy.&#xD;
&#xD;
      The primary variables were:&#xD;
&#xD;
        -  the rate of patients with documented infections&#xD;
&#xD;
        -  the time to platelet engraftment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of infections</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to platelet engraftment</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Hodgkin's Disease</condition>
  <condition>Non-Hodgkin Lymphomas</condition>
  <condition>Multiple Myelomas</condition>
  <arm_group>
    <arm_group_label>A: lenograstim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>total group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenograstim</intervention_name>
    <arm_group_label>A: lenograstim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of histologically proven lymphoproliferative disease specified as Hodgkin's&#xD;
             disease, non-Hodgkin's lymphoma (NHL) or multiple myeloma&#xD;
&#xD;
          -  Indication of high-dose therapy and autologous peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Availability of a sufficient amount of blood stem cells (CD34+ cells &gt;= 2.0 x 106/kg)&#xD;
&#xD;
          -  Age between 18 and 70 years&#xD;
&#xD;
          -  High-dose therapy with one of the following high-dose regimes: Melphalan 140 mg/m2 or&#xD;
             200 mg/m2, BEAM, BEAC, BUCY or CBV (the last permitted according to amendment 2, see&#xD;
             Section 9.8.1)&#xD;
&#xD;
          -  Patient's written consent to participation in this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous high-dose therapy and blood stem cell transplantation except for melphalan&#xD;
             140 mg/m2 or 200 mg/m2 in patients with multiple myeloma who did not participate in&#xD;
             the cytocapacity test previously (according to amendment 2, see Section 9.8.1).&#xD;
&#xD;
          -  Known intolerance to lenograstim&#xD;
&#xD;
          -  Out-patient therapy following high-dose therapy and blood stem cell transplantation&#xD;
&#xD;
          -  Myocardial infarction &lt; 6 months prior to inclusion into the study&#xD;
&#xD;
          -  Cardiac arrhythmias Lown IV b&#xD;
&#xD;
          -  Clinically manifest cardiac insufficiency (&gt; NYHA II)&#xD;
&#xD;
          -  Renal insufficiency with serum creatinine &gt; 2 mg%&#xD;
&#xD;
          -  Hepatic diseases with elevated levels of transaminases and bilirubin greater than&#xD;
             3-fold above normal&#xD;
&#xD;
          -  Severe infections (HIV, Hepatitis B/C)&#xD;
&#xD;
          -  Severe psychiatric diseases&#xD;
&#xD;
          -  Non-curative treatment of other malignoma within the past 5 years&#xD;
&#xD;
          -  Pregnant women or women breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>March 10, 2010</last_update_submitted>
  <last_update_submitted_qc>March 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Christian Straka</name_title>
    <organization>Univ. of Munich (LMU)</organization>
  </responsible_party>
  <keyword>Lymphoproliferative diseases (Hodgkin's disease, non-Hodgkin's lymphomas, multiple myelomas) and high-dose therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

